Purple Book product · Reference 351(a)
Arexvy
Respiratory Syncytial Virus Vaccine, Adjuvanted
At a glance
May 03, 2023
Approved
Reference 351(a)
License type
Rx
Marketing
No
Patents listed
Key dates
First licensure
Date the BLA was first licensed.
May 03, 2023
3 yr 2 mo ago
Approval
Approval date of this BLA submission.
May 03, 2023
3 yr 2 mo ago
Today
Reference product exclusivity ends
12-year reference-product exclusivity window per BPCIA §351(k)(7).
May 03, 2035
in 9 yr 1 mo
Pharmaceutical detail
Strength
120UG/.5ML
Dosage form
For Injection
Route
Intramuscular
Presentation
Single-Dose Vial
Center
CBER
License number
1617
Product number
001
Submission type
Original
Supplement number
0
Change type
Not listed
Reference product family
View full familyThis is the reference (originator) product. Biosimilars and interchangeables referencing it are listed below.
Patent list
No patent-list records were published for this product. The Purple Book patent list reflects the statutory patent exchange under the BPCIA and is not exhaustive.
Taxonomy and ontology
12 termscenter
Center for Biologics Evaluation and Research
center · CBER
application pathway
Biologics License Application
blaNumber · BLA
license type
351(a)
blaType · 351(a)
application pathway
Section 351(a) Biologic
blaType · 351(a)
product role
Reference or Standalone Biologic
blaType · Reference product
marketing status
Prescription
marketingStatus · Rx
licensure status
Licensed
licensure · Licensed
route
Intramuscular
routeOfAdministration · Intramuscular
dosage form
For Injection
dosageForm · For Injection
source kind
Monthly Download
sourceKind · monthly_download
- Food and Drug Administrationparent ofCenter for Biologics Evaluation and Research
- Food and Drug Administrationsource forMonthly Download
- Biologics License Applicationparent ofSection 351(a) Biologic
- Biologics License Applicationparent ofSection 351(k) Biosimilar or Interchangeable
- Section 351(a) Biologicmaps to351(a)
- 351(a)classifiesReference or Standalone Biologic
Source provenance
